EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

New Hepatocellular Carcinoma (HCC) Primary Cell Cultures as Models for Exploring Personalized Anti-TGF-β Therapies Based on Tumor Characteristics

Rosanna Scialpi, Rut Espinosa-Sotelo, Esther Bertran, Francesco Dituri, Gianluigi Giannelli iD, Isabel Fabregat iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26062430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Rosanna Scialpi und 5 weiteren Autor:innen. Beteiligte Einrichtung: TGF-β and Cancer Group-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), 08860 L'Hospitalet de Llobregat, Spain. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Transforming Growth Factor beta. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Científica Asociación Española contra el cáncer (AECC), Ministerio de Ciencia e Innovación (MICINN-AEI), Spain, National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBEREHD - ISCIII).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transforming growth factor-beta (TGF-β) plays a dual role in hepatocellular carcinoma (HCC), acting as a tumor suppressor in early stages by inducing cell cycle arrest and apoptosis, and as a promoter in advanced stages by fostering tumor progression, epithelial–mesenchymal transition (EMT), and metastasis. Understanding TGF-β’s role in HCC progression, particularly its impact on tumor–stroma interactions, is crucial for developing personalized therapies. This study aims to clarify TGF-β function in HCC using patient-derived cell lines and advanced 2D and 3D culture models. Three new cell lines (HLC21, HLC19 tumoral, and HLC19 metastatic) were isolated from HCC patient biopsies, characterizing their phenotypic markers and responses to TGF-β and its inhibitor, galunisertib. HLC21 cells displayed a mixed epithelial–mesenchymal phenotype, responding to TGF-β suppressing growth and undergoing EMT, which were inhibited by galunisertib. Conversely, HLC19 tumoral and metastatic cells exhibited mesenchymal phenotypes and were resistant to both TGF-β suppression and galunisertib effects. In 3D co-cultures with hepatic fibroblasts, TGF-β inhibitory effects were diminished for responsive cell lines, while resistant lines maintained their non-responsiveness. These findings highlight TGF-β’s dual role in HCC and its influence on tumor–stroma crosstalk, offering valuable models for exploring personalized anti-TGF-β therapies based on tumor characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsTransforming Growth Factor betaHumansEpithelial-Mesenchymal TransitionQuinolinesCell Line, TumorPyrazolesPrimary Cell CulturePrecision MedicineCoculture TechniquesCell Proliferation

Stichwörter der Autor:innen

EMTTGF-beta inhibitorshepatic stellate cellsliver cancerliver tumor spheroidsstemness

Substanzen

Transforming Growth Factor betaLY-2157299QuinolinesPyrazoles

Autor:innen und Institutionen

  • TGF-β and Cancer Group-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), 08860 L'Hospitalet de Llobregat, Spain.
  • Medical Oncology Unit, National Institute of Gastroenterology, IRCCS "S. De Bellis" Research Hospital, 70013 Castellana Grotte, Italy.
  • National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain.

ORCID-Profile: Gianluigi Giannelli, Isabel Fabregat

Förderung

  • Fundación Científica Asociación Española contra el cáncer (AECC)
  • Ministerio de Ciencia e Innovación (MICINN-AEI), Spain
  • National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBEREHD - ISCIII)
  • SGR program, AGAUR, Generalitat de Catalunya
  • CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases
  • AGAUR-SGR program
  • CERCA program

Zitieren

APA

Scialpi, R., Espinosa-Sotelo, R., Bertran, E., Dituri, F., Giannelli, G., & Fabregat, I. (2025). New Hepatocellular Carcinoma (HCC) Primary Cell Cultures as Models for Exploring Personalized Anti-TGF-β Therapies Based on Tumor Characteristics. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062430

Vancouver

Scialpi R, Espinosa-Sotelo R, Bertran E, Dituri F, Giannelli G, Fabregat I. New Hepatocellular Carcinoma (HCC) Primary Cell Cultures as Models for Exploring Personalized Anti-TGF-β Therapies Based on Tumor Characteristics. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062430

BibTeX
@article{Scialpi2025,
  author = {Scialpi, Rosanna and Espinosa-Sotelo, Rut and Bertran, Esther and Dituri, Francesco and Giannelli, Gianluigi and Fabregat, Isabel},
  title = {New Hepatocellular Carcinoma (HCC) Primary Cell Cultures as Models for Exploring Personalized Anti-TGF-β Therapies Based on Tumor Characteristics},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26062430}
}
Kostenlos starten →